Global Human Vaccines Market - Technologies, Market share and Industry Forecast to 2024

  • ID: 4557649
  • Report
  • Region: Global
  • 240 Pages
  • Occams Business Research and Consulting
1 of 4
The Global Human Vaccines Market is Expected to Rise With a CAGR of 11.3% During the Forecast Period, 2017-2024.

FEATURED COMPANIES

  • Astrazeneca Plc (U.K.)
  • Bavarian Nordic (Denmark)
  • Bio Med (U.K.)
  • Johnson & Johnson (U.S.)
  • Lupin (India)
  • Merck & Co. Inc. (U.S.)
  • MORE

Global human vaccines market is expected to rise with a CAGR of 11.3% during forecast period 2017-2024. Key factors driving the market growth are growing awareness regarding vaccination and immunization program, surging demand for pediatric vaccines, rising prevalence of infectious diseases and improving healthcare infrastructure. Stringent regulatory process and adverse side effects of vaccines are expected to restrain the market growth. However, increase in investment for human vaccines and emergence of novel vaccines and resistant strains are expected to provide lucrative market opportunities. Vaccine storage and handling issues and inadequate vaccination coverage is expected to challenge the market growth.

Geographically, global human vaccines is segmented into North America, Europe, Asia Pacific and RoW. North America is the leading region for global human vaccines market in terms of market revenue share in 2017. This is due to the increasing number of regulatory approvals of human vaccines in U.S., Canada, etc., surging demand for vaccination among adults and children, increase in government efforts toward vaccination programs, etc. are expected to fuel the growth of North America human vaccines market. However, Asia Pacific is expected to register highest market growth during forecast period 2017-2024 due to the increasing focus of government organizations in Asia Pacific countries such as China, India, Japan, etc. towards the immunization for various diseases such as polio, rotavirus, flu, and typhoid.

Global human vaccines market report covers segmentation analysis of vaccine type, product, age group and distribution channel. On the basis of vaccines types, market is segmented into conjugate vaccine, recombinant vaccine, inactivated vaccine, combination vaccine, attenuated vaccine and others vaccine. Conjugate vaccines is the leading vaccine type segment due to the increased adoption of conjugate vaccines for adults, technological advancements in conjugate vaccines, regulatory approvals for regulatory vaccines, etc. On the basis of products, market is segmented into Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles and Mumps, Typhoid, Combination and Others. Pneumococcal vaccines is the leading product segment due to rising prevalence of pneumococcal diseases, emergence of protein-based combination pneumococcal vaccines. On the basis of age group, market is segmented into Pediatrics, Adolescents, Adults and Geriatrics. Pediatric vaccines accounted for the largest market share in 2017 owing to the increasing prevalence of infectious diseases, polio, pneumonia, etc. among children worldwide. Whereas, adult vaccines is expected to witness highest CAGR through 2024. On the basis of distribution channel, market is segmented into Hospital Pharmacies, Drugstores and Others. Hospital Pharmacies is the leading distribution channel segment owing to the increasing number of hospitals and diagnostic centers, increasing healthcare expenditure, etc.

Global human vaccines market is influenced by the presence of leading human vaccines manufacturers, such as Abbott Laboratories (U.S.), Astrazeneca PLC (UK), Dynavax Technologies (U.S.), Pfizer Inc. (U.S.) and others. Product launch, joint venture, merger and acquisition are some of the crucial strategies adopted by the key market players to gain competitive advantage.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astrazeneca Plc (U.K.)
  • Bavarian Nordic (Denmark)
  • Bio Med (U.K.)
  • Johnson & Johnson (U.S.)
  • Lupin (India)
  • Merck & Co. Inc. (U.S.)
  • MORE

1. Introduction
1.1. Executive Summary
1.2. Estimation Methodology

2. Market Overview
2.1. Global Human Vaccines Market: Evolution & Transition
2.2. Market Definition & Scope
2.3. Industry Structure
2.4. Regulatory Framework
2.5. Total Market Analysis
2.5.1. Top 5 Findings
2.5.2. Top 5 Opportunity Markets
2.5.3. Top 5 Companies
2.5.4. Top 3 Competitive Strategies
2.6. Estimation Analysis
2.7. Strategic Analysis
2.7.1. Investment Vs. Adoption Model
2.7.2. 360-Degree Industry Analysis
2.7.3. Porters 5 Force Model
2.7.4. See-Saw Analysis
2.7.5. Consumer Analysis And Key Buying Criteria
2.8. Competitive Analysis
2.8.1. Market Share Analysis & Top Company Analysis
2.9. Strategic Recommendations & Key Conclusions
2.9.1. Investment Opportunities By Regions
2.9.2. Opportunities In Emerging Applications
2.9.3. Investment Opportunity In Fastest Growing Segment

3. Market Determinants
3.1. Market Drivers
3.1.1. Growing Awareness Regarding Vaccination And Immunization Programs
3.1.2. Surging Demand For Pediatric Vaccines
3.1.3. Rising Prevalence Of Infectious Diseases
3.1.4. Improving Healthcare Infrastructure
3.2. Market Restraints
3.2.1. Stringent Regulatory Process
3.2.2. Adverse Side Effects Of Vaccines
3.3. Market Opportunities
3.3.1. Increase In Investment For Human Vaccines
3.3.2. Emergence Of Novel Vaccines And Resistant Strains
3.4. Market Challenges
3.4.1. Vaccine Storage And Handling Issues
3.4.2. Inadequate Vaccination Coverage

4. Global Human Vaccines Market By Vaccine Type
4.1. Market Definition And Scope
4.2. Decision Support Database & Estimation Methodology
4.3. Comparative Analysis Across Market Segments
4.4. Opportunity Matrix
4.5. Market Segmentation
4.5.1. Global Conjugate Vaccine Market
4.5.1.1. Adoption Scenario & Market Determinants
4.5.1.2. Market Estimations And Forecasts 2015-2024 ($ Million)
4.5.1.3. Key Players & Key Products
4.5.1.4. Key Conclusions
4.5.2. Global Recombinant Vaccine Market
4.5.2.1. Adoption Scenario & Market Determinants
4.5.2.2. Market Estimations And Forecasts 2015-2024 ($ Million)
4.5.2.3. Key Players & Key Products
4.5.2.4. Key Conclusions
4.5.3. Global Inactivated Vaccine Market
4.5.3.1. Adoption Scenario & Market Determinants
4.5.3.2. Market Estimations And Forecasts 2015-2024 ($ Million)
4.5.3.3. Key Players & Key Products
4.5.3.4. Key Conclusions
4.5.4. Global Combination Vaccine Market
4.5.4.1. Adoption Scenario & Market Determinants
4.5.4.2. Market Estimations And Forecasts 2015-2024 ($ Million)
4.5.4.3. Key Players & Key Products
4.5.4.4. Key Conclusions
4.5.5. Global Attenuated Vaccine Market
4.5.5.1. Adoption Scenario & Market Determinants
4.5.5.2. Market Estimations And Forecasts 2015-2024 ($ Million)
4.5.5.3. Key Players & Key Products
4.5.5.4. Key Conclusions
4.5.6. Global Others Market
4.5.6.1. Adoption Scenario & Market Determinants
4.5.6.2. Market Estimations And Forecasts 2015-2024 ($ Million)
4.5.6.3. Key Players & Key Products
4.5.6.4. Key Conclusions

5. Global Human Vaccines Market By Product
5.1. Market Definition And Scope
5.2. Decision Support Database & Estimation Methodology
5.3. Comparative Analysis Across Market Segments
5.4. Opportunity Matrix
5.5. Market Segmentation
5.5.1. Global Pneumococcal Market
5.5.1.1. Adoption Scenario & Market Determinants
5.5.1.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.1.3. Key Players & Key Products
5.5.1.4. Key Conclusions
5.5.2. Global Influenza Market
5.5.2.1. Adoption Scenario & Market Determinants
5.5.2.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.2.3. Key Players & Key Products
5.5.2.4. Key Conclusions
5.5.3. Global Hepatitis Market
5.5.3.1. Adoption Scenario & Market Determinants
5.5.3.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.3.3. Key Players & Key Products
5.5.3.4. Key Conclusions
5.5.4. Global HPV Market
5.5.4.1. Adoption Scenario & Market Determinants
5.5.4.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.4.3. Key Players & Key Products
5.5.4.4. Key Conclusions
5.5.5. Global Meningococcal Market
5.5.5.1. Adoption Scenario & Market Determinants
5.5.5.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.5.3. Key Players & Key Products
5.5.5.4. Key Conclusions
5.5.6. Global Rotavirus Market
5.5.6.1. Adoption Scenario & Market Determinants
5.5.6.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.6.3. Key Players & Key Products
5.5.6.4. Key Conclusions
5.5.7. Global Measles And Mumps Market
5.5.7.1. Adoption Scenario & Market Determinants
5.5.7.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.7.3. Key Players & Key Products
5.5.7.4. Key Conclusions
5.5.8. Global Typhoid Market
5.5.8.1. Adoption Scenario & Market Determinants
5.5.8.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.8.3. Key Players & Key Products
5.5.8.4. Key Conclusions
5.5.9. Global Combination Market
5.5.9.1. Adoption Scenario & Market Determinants
5.5.9.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.9.3. Key Players & Key Products
5.5.9.4. Key Conclusions
5.5.10. Global Others Market
5.5.10.1. Adoption Scenario & Market Determinants
5.5.10.2. Market Estimations And Forecasts 2015-2024 ($ Million)
5.5.10.3. Key Players & Key Products
5.5.10.4. Key Conclusions

6. Global Human Vaccines Market By Age Group
6.1. Market Definition And Scope
6.2. Decision Support Database & Estimation Methodology
6.3. Comparative Analysis Across Market Segments
6.4. Opportunity Matrix
6.5. Market Segmentation
6.5.1. Global Pediatrics Market
6.5.1.1. Adoption Scenario & Market Determinants
6.5.1.2. Market Estimations And Forecasts 2015-2024 ($ Million)
6.5.1.3. Key Players & Key Products
6.5.1.4. Key Conclusions
6.5.2. Global Adolescents Market
6.5.2.1. Adoption Scenario & Market Determinants
6.5.2.2. Market Estimations And Forecasts 2015-2024 ($ Million)
6.5.2.3. Key Players & Key Products
6.5.2.4. Key Conclusions
6.5.3. Global Adults Market
6.5.3.1. Adoption Scenario & Market Determinants
6.5.3.2. Market Estimations And Forecasts 2015-2024 ($ Million)
6.5.3.3. Key Players & Key Products
6.5.3.4. Key Conclusions
6.5.4. Global Geriatrics Market
6.5.4.1. Adoption Scenario & Market Determinants
6.5.4.2. Market Estimations And Forecasts 2015-2024 ($ Million)
6.5.4.3. Key Players & Key Products
6.5.4.4. Key Conclusions

7. Global Human Vaccines Market By Distribution Channel
7.1. Market Definition And Scope
7.2. Decision Support Database & Estimation Methodology
7.3. Comparative Analysis Across Market Segments
7.4. Opportunity Matrix
7.5. Market Segmentation
7.5.1. Global Hospital Pharmacies Market
7.5.1.1. Adoption Scenario & Market Determinants
7.5.1.2. Market Estimations And Forecasts 2015-2024 ($ Million)
7.5.1.3. Key Players & Key Products
7.5.1.4. Key Conclusions
7.5.2. Global Drugstores Market
7.5.2.1. Adoption Scenario & Market Determinants
7.5.2.2. Market Estimations And Forecasts 2015-2024 ($ Million)
7.5.2.3. Key Players & Key Products
7.5.2.4. Key Conclusions
7.5.3. Global Others Market
7.5.3.1. Adoption Scenario & Market Determinants
7.5.3.2. Market Estimations And Forecasts 2015-2024 ($ Million)
7.5.3.3. Key Players & Key Products
7.5.3.4. Key Conclusions

8. Competitive Landscape
8.1. Key Strategies
8.1.1. List Of Mergers And Acquisition
8.1.2. List Of Joint Ventures
8.1.3. List Of Product Launches
8.1.4. List Of Partnerships

9. Geographic Analysis
9.1. Decision Support Database & Estimation Methodology
9.2. Comparative Analysis Across Market Segments
9.3. Opportunity Matrix
9.4. Global Human Vaccines Market By Region 2015-2024
9.4.1. North America
9.4.1.1. Industry Analysis 2015-2024 ($ Million)
9.4.1.2. Top Country Analysis
9.4.1.2.1. U.S.
9.4.1.2.1.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.1.2.1.2. Key Players & Key Products
9.4.1.2.1.3. Key Conclusions
9.4.1.2.2. Canada
9.4.1.2.2.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.1.2.2.2. Key Players & Key Products
9.4.1.2.2.3. Key Conclusions
9.4.2. Europe
9.4.2.1. Industry Analysis 2015-2024 ($ Million)
9.4.2.2. Top Country Analysis
9.4.2.2.1. U.K.
9.4.2.2.1.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.2.2.1.2. Key Players & Key Products
9.4.2.2.1.3. Key Conclusions
9.4.2.2.2. France
9.4.2.2.2.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.2.2.2.2. Key Players & Key Products
9.4.2.2.2.3. Key Conclusions
9.4.2.2.3. Germany
9.4.2.2.3.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.2.2.3.2. Key Players & Key Products
9.4.2.2.3.3. Key Conclusions
9.4.2.2.4. Spain
9.4.2.2.4.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.2.2.4.2. Key Players & Key Products
9.4.2.2.4.3. Key Conclusions
9.4.2.2.5. Rest Of Europe
9.4.2.2.5.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.2.2.5.2. Key Players & Key Products
9.4.2.2.5.3. Key Conclusions
9.4.3. Asia Pacific
9.4.3.1. Industry Analysis 2015-2024 ($ Million)
9.4.3.2. Top Country Analysis
9.4.3.2.1. China
9.4.3.2.1.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.3.2.1.2. Key Players & Key Products
9.4.3.2.1.3. Key Conclusions
9.4.3.2.2. India
9.4.3.2.2.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.3.2.2.2. Key Players & Key Products
9.4.3.2.2.3. Key Conclusions
9.4.3.2.3. Japan
9.4.3.2.3.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.3.2.3.2. Key Players & Key Products
9.4.3.2.3.3. Key Conclusions
9.4.3.2.4. Australia
9.4.3.2.4.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.3.2.4.2. Key Players & Key Products
9.4.3.2.4.3. Key Conclusions
9.4.3.2.5. Rest Of Asia Pacific
9.4.3.2.5.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.3.2.5.2. Key Players & Key Products
9.4.3.2.5.3. Key Conclusions
9.4.4. ROW
9.4.4.1. Industry Analysis 2015-2024 ($ Million)
9.4.4.2. Top Country Analysis
9.4.4.2.1. Latin America
9.4.4.2.1.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.4.2.1.2. Key Players & Key Products
9.4.4.2.1.3. Key Conclusions
9.4.4.2.2. Middle East & Africa
9.4.4.2.2.1. Market Estimations And Forecasts 2015-2024 ($ Million)
9.4.4.2.2.2. Key Players & Key Products
9.4.4.2.2.3. Key Conclusions

10. Company Profiles
10.1. Abbott Laboratories (U.S.)
10.1.1. Overview
10.1.2. Product Portfolio
10.1.3. Strategic Initiatives
10.1.4. Scot Analysis
10.1.5. Strategic Analysis
10.2. Astrazeneca Plc (U.K.)
10.2.1. Overview
10.2.2. Product Portfolio
10.2.3. Strategic Initiatives
10.2.4. Scot Analysis
10.2.5. Strategic Analysis
10.3. Bavarian Nordic (Denmark)
10.3.1. Overview
10.3.2. Product Portfolio
10.3.3. Strategic Initiatives
10.3.4. Scot Analysis
10.3.5. Strategic Analysis
10.4. Bio Med (U.K.)
10.4.1. Overview
10.4.2. Product Portfolio
10.4.3. Strategic Initiatives
10.4.4. Scot Analysis
10.4.5. Strategic Analysis
10.5. Dynavax Technologies (U.S.)
10.5.1. Overview
10.5.2. Product Portfolio
10.5.3. Strategic Initiatives
10.5.4. Scot Analysis
10.5.5. Strategic Analysis
10.6. Glaxosmithkline Plc (U.K.)
10.6.1. Overview
10.6.2. Product Portfolio
10.6.3. Strategic Initiatives
10.6.4. Scot Analysis
10.6.5. Strategic Analysis
10.7. Johnson & Johnson (U.S.)
10.7.1. Overview
10.7.2. Product Portfolio
10.7.3. Strategic Initiatives
10.7.4. Scot Analysis
10.7.5. Strategic Analysis
10.8. Lupin (India)
10.8.1. Overview
10.8.2. Product Portfolio
10.8.3. Strategic Initiatives
10.8.4. Scot Analysis
10.8.5. Strategic Analysis
10.9. Merck & Co. Inc. (U.S.)
10.9.1. Overview
10.9.2. Product Portfolio
10.9.3. Strategic Initiatives
10.9.4. Scot Analysis
10.9.5. Strategic Analysis
10.10. Novartis (Switzerland)
10.10.1. Overview
10.10.2. Product Portfolio
10.10.3. Strategic Initiatives
10.10.4. Scot Analysis
10.10.5. Strategic Analysis
10.11. Panacea Biotec (India)
10.11.1. Overview
10.11.2. Product Portfolio
10.11.3. Strategic Initiatives
10.11.4. Scot Analysis
10.11.5. Strategic Analysis
10.12. Pfizer Inc. (U.S.)
10.12.1. Overview
10.12.2. Product Portfolio
10.12.3. Strategic Initiatives
10.12.4. Scot Analysis
10.12.5. Strategic Analysis
10.13. Sanofi (France)
10.13.1. Overview
10.13.2. Product Portfolio
10.13.3. Strategic Initiatives
10.13.4. Scot Analysis
10.13.5. Strategic Analysis
10.14. Takeda Pharmaceutical (Japan)
10.14.1. Overview
10.14.2. Product Portfolio
10.14.3. Strategic Initiatives
10.14.4. Scot Analysis
10.14.5. Strategic Analysis
10.15. Zydus Cadila (India)
10.15.1. Overview
10.15.2. Product Portfolio
10.15.3. Strategic Initiatives
10.15.4. Scot Analysis
10.15.5. Strategic Analysis

List Of Tables:
1. Global Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
2. Global Conjugate Vaccine Market By Geography 2015-2024 ($ Million)
3. Global Recombinant Vaccine Market By Geography 2015-2024 ($ Million)
4. Global Inactivated Vaccine Market By Geography 2015-2024 ($ Million)
5. Global Combination Vaccine Market By Geography 2015-2024 ($ Million)
6. Global Attenuated Vaccine Market By Geography 2015-2024 ($ Million)
7. Global Others Market By Geography 2015-2024 ($ Million)
8. Global Human Vaccines Market By Product 2015-2024 ($ Million)
9. Global Pneumococcal Market By Geography 2015-2024 ($ Million)
10. Global Influenza Market By Geography 2015-2024 ($ Million)
11. Global Hepatitis Market By Geography 2015-2024 ($ Million)
12. Global HPV Market By Geography 2015-2024 ($ Million)
13. Global Meningococcal Market By Geography 2015-2024 ($ Million)
14. Global Rotavirus Market By Geography 2015-2024 ($ Million)
15. Global Measles And Mumps Market By Geography 2015-2024 ($ Million)
16. Global Typhoid Market By Geography 2015-2024 ($ Million)
17. Global Combination Market By Geography 2015-2024 ($ Million)
18. Global Others Market By Geography 2015-2024 ($ Million)
19. Global Human Vaccines Market By Age Group 2015-2024 ($ Million)
20. Global Pediatrics Market By Geography 2015-2024 ($ Million)
21. Global Adolescents Market By Geography 2015-2024 ($ Million)
22. Global Adults Market By Geography 2015-2024 ($ Million)
23. Global Geriatrics Market By Geography 2015-2024 ($ Million)
24. Global Human Vaccines Market By Distribution Channel 2015-2024 ($ Million)
25. Global Hospital Pharmacies Market By Geography 2015-2024 ($ Million)
26. Global Drugstores Market By Geography 2015-2024 ($ Million)
27. Global Others Market By Geography 2015-2024 ($ Million)
28. North America Human Vaccines Market 2015-2024 ($ Million)
29. Europe Human Vaccines Market 2015-2024 ($ Million)
30. Asia Pacific Human Vaccines Market 2015-2024 ($ Million)
31. Rest Of The World Human Vaccines Market 2015-2024 ($ Million)
32. North America Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
33. Europe Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
34. Asia Pacific Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
35. Rest Of The World Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
36. North America Human Vaccines Market By Product 2015-2024 ($ Million)
37. Europe Human Vaccines Market By Product 2015-2024 ($ Million)
38. Asia Pacific Human Vaccines Market By Product 2015-2024 ($ Million)
39. Rest Of The World Human Vaccines Market By Product 2015-2024 ($ Million)
40. North America Human Vaccines Market By Age Group 2015-2024 ($ Million)
41. Europe Human Vaccines Market By Age Group 2015-2024 ($ Million)
42. Asia Pacific Human Vaccines Market By Age Group 2015-2024 ($ Million)
43. Rest Of The World Human Vaccines Market By Age Group 2015-2024 ($ Million)
44. North America Human Vaccines Market By Distribution Channel 2015-2024 ($ Million)
45. Europe Human Vaccines Market By Distribution Channel 2015-2024 ($ Million)
46. Asia Pacific Human Vaccines Market By Distribution Channel 2015-2024 ($ Million)
47. Rest Of The World Human Vaccines Market By Distribution Channel 2015-2024 ($ Million)
48. United States Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
49. United States Human Vaccines Market By Product 2015-2024 ($ Million)
50. Canada Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
51. Canada Human Vaccines Market By Product 2015-2024 ($ Million)
52. U.K. Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
53. U.K. Human Vaccines Market By Product 2015-2024 ($ Million)
54. Germany Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
55. Germany Human Vaccines Market By Product 2015-2024 ($ Million)
56. France Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
57. France Human Vaccines Market By Product 2015-2024 ($ Million)
58. Spain Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
59. Spain Human Vaccines Market By Product 2015-2024 ($ Million)
60. ROE Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
61. ROE Human Vaccines Market By Product 2015-2024 ($ Million)
62. India Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
63. India Human Vaccines Market By Product 2015-2024 ($ Million)
64. China Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
65. China Human Vaccines Market By Product 2015-2024 ($ Million)
66. Japan Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
67. Japan Human Vaccines Market By Product 2015-2024 ($ Million)
68. Australia Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
69. Australia Human Vaccines Market By Product 2015-2024 ($ Million)
70. ROAPAC Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
71. ROAPAC Human Vaccines Market By Product 2015-2024 ($ Million)
72. Latin America Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
73. Latin America Human Vaccines Market By Product 2015-2024 ($ Million)
74. MENA Human Vaccines Market By Vaccine Type 2015-2024 ($ Million)
75. MENA Human Vaccines Market By Product 2015-2024 ($ Million)

List Of Figures:
1. Global Conjugate Vaccine Market 2015-2024 ($ Million)
2. Global Recombinant Vaccine Market 2015-2024 ($ Million)
3. Global Inactivated Vaccine Market 2015-2024 ($ Million)
4. Global Combination Vaccine Market 2015-2024 ($ Million)
5. Global Attenuated Vaccine Market 2015-2024 ($ Million)
6. Global Others Market 2015-2024 ($ Million)
7. Global Pneumococcal Market 2015-2024 ($ Million)
8. Global Influenza Market 2015-2024 ($ Million)
9. Global Hepatitis Market 2015-2024 ($ Million)
10. Global Hpv Market 2015-2024 ($ Million)
11. Global Meningococcal Market 2015-2024 ($ Million)
12. Global Rotavirus Market 2015-2024 ($ Million)
13. Global Measles And Mumps Market 2015-2024 ($ Million)
14. Global Typhoid Market 2015-2024 ($ Million)
15. Global Combination Market 2015-2024 ($ Million)
16. Global Others Market 2015-2024 ($ Million)
17. Global Pediatrics Market 2015-2024 ($ Million)
18. Global Adolescents Market 2015-2024 ($ Million)
19. Global Adults Market 2015-2024 ($ Million)
20. Global Geriatrics Market 2015-2024 ($ Million)
21. Global Hospital Pharmacies Market 2015-2024 ($ Million)
22. Global Drugstores Market 2015-2024 ($ Million)
23. Global Others Market 2015-2024 ($ Million)
24. United States (U.S.) Human Vaccines Market 2015-2024 ($ Million)
25. Canada Human Vaccines Market 2015-2024 ($ Million)
26. United Kingdom (U.K.) Human Vaccines Market 2015-2024 ($ Million)
27. France Human Vaccines Market 2015-2024 ($ Million)
28. Germany Human Vaccines Market 2015-2024 ($ Million)
29. Spain Human Vaccines Market 2015-2024 ($ Million)
30. ROE Human Vaccines Market 2015-2024 ($ Million)
31. India Human Vaccines Market 2015-2024 ($ Million)
32. China Human Vaccines Market 2015-2024 ($ Million)
33. Japan Human Vaccines Market 2015-2024 ($ Million)
34. Australia Human Vaccines Market 2015-2024 ($ Million)
35. ROAPAC Human Vaccines Market 2015-2024 ($ Million)
36. Latin America Human Vaccines Market 2015-2024 ($ Million)
37. MENA Human Vaccines Market 2015-2024 ($ Million)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories (U.S.)
  • Astrazeneca Plc (U.K.)
  • Bavarian Nordic (Denmark)
  • Bio Med (U.K.)
  • Dynavax Technologies (U.S.)
  • Glaxosmithkline Plc (U.K.)
  • Johnson & Johnson (U.S.)
  • Lupin (India)
  • Merck & Co. Inc. (U.S.)
  • Novartis (Switzerland)
  • Panacea Biotec (India)
  • Pfizer Inc. (U.S.)
  • Sanofi (France)
  • Takeda Pharmaceutical (Japan)
  • Zydus Cadila (India)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll